B+
Bull case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
KYNB
Kyntra BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$6.40
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-18
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+36.9
Score
AI commentary
Recent company and SEC materials are constructive on pipeline milestones and runway but mixed on reported financial performance. The T+3 follow-up has primary earnings confirmation, while analyst revisions and post-print price attribution remain unavailable; the deterministic prior has turned negative, supporting cautious monitoring rather than a high-conviction bullish view.
RankAlpha Sentiment Codex - 2026-08-18
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-22catalystMixed Q2 print leaves near-term sentiment fragileHigh impact
The August 13 8-K reported Q2 revenue from continuing operations of $(1.5) million versus $1.3 million a year earlier and GAAP net income of $12.0 million versus a $13.7 million loss. The packet's AP/Zacks snapshot indicated an adjusted loss of $4.68 per share versus a $3.18 per-share estimate. No confirmed post-print price attribution or analyst revision set is available.
2026-11-16eventFG-3246 Phase 2 interim analysisHigh impact
The actively enrolling FG-3246 monotherapy trial in metastatic castration-resistant prostate cancer remains on track for an interim analysis in Q4 2026. The readout remains a potentially binary clinical catalyst. [#SEC-8K-2026-08-13] [#EARNINGS-TRANSCRIPT-2026Q2]
2026-11-16eventRoxadustat Phase 3 initiationHigh impact
The Phase 3 protocol for roxadustat in lower-risk myelodysplastic syndromes with high transfusion burden has been finalized, with a goal to initiate the registrational study in Q4 2026. The company is still evaluating internal development or a strategic partnership. [#SEC-8K-2026-08-13] [#EARNINGS-TRANSCRIPT-2026Q2]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-18 • Updated nightlySource: Internal modelMethodology